EVErolimus for Renal Cancer Ensuing Surgical Therapy:  S0931

• Disease Stage:  Diagnosed with renal cell carcinoma (clear cell or non-clear cell) that is determined to be at high risk for recurrence.
• Status:  Recruiting
• Sponsor:  Southwest Oncology Group (SWOG)/ NCI
• Title: EVEREST:  EVErolimus for Renal Cancer Ensuing Surgical Therapy:  S0931
• Phase:  III
• Purpose:  The purpose of this study is to see whether treatment with everolimus after surgery for kidney cancer will increase the remission time.  The current standard treatment after surgery is careful monitoring with no immediate treatment.  Studies suggest that one way kidney cancer may grow is through chemical signaling through a protein named “mTOR”.  Everolimus is a drug that stops signaling through mTOR and may therefore stop the growth of kidney cancer.

Eligibility 

• >/= 18 yrs.
• Have had surgery to remove all the kidney cancer
• Must be enrolled within 84 days of final surgery
• Must be free of any metastatic disease

Contact:  772-288-5858, option 4

Contact Us

Robert and Carol Weissman Cancer Center
Clinical Research Program
501 E. Osceola St.
Stuart, FL 34994
(772) 288-5858, prompt #4